Valbiotis
La Rochelle
About Valbiotis
Valbiotis develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trials for the treatment of type 2 diabetes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $29.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2022)
- Ticker: epa:ALVAL
- Website: valbiotis.com
- Phone: +33 54-628-6258
Industries & Categories
Biotechnology, Clinical Trials, Product Research
Social Profiles
Canonical: https://fsome.com/organization/valbiotis-184407 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.